NCT06752122View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of RCS-21 in Healthy Volunteers.

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 18, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

March 31, 2026

Conditions
Healthy VolunteersSafetyTolerabilityPharmacokinetics
Interventions
DRUG

Placebo (in SAD)

Inhalation once daily in the SAD part

DRUG

RCS-21 (in SAD)

Inhalation once daily in the SAD part

DRUG

Placebo (MAD)

Inhalation once daily for seven days in the MAD part

DRUG

RCS-21 (in MAD)

Inhalation once daily for seven days in the MAD part

Trial Locations (1)

30625

RECRUITING

Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), Hanover

All Listed Sponsors
collaborator

LungenClinic Grosshansdorf

OTHER

lead

RNATICS GmbH

INDUSTRY